Could a Crohn's drug tame a rare stomach disease?
NCT ID NCT06317220
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether vedolizumab (Entyvio), a drug used for inflammatory bowel disease, can reduce symptoms of collagenous gastritis—a rare condition causing stomach pain, nausea, and bloating. Eleven participants receive the drug via IV and report their symptoms over 12 weeks. The study also checks safety and how long any benefits last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vedolizumab (Entyvio)
- What this could lead to
- If it works, this could point toward a treatment for collagenous gastritis, a rare stomach condition with limited options.
- What could go wrong
- This is a very small, early-phase trial with only 11 participants, so results may not apply to everyone. Vedolizumab also carries risks like allergic reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLLAGENOUS GASTRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States